Compare · AKBA vs FGEN
AKBA vs FGEN
Side-by-side comparison of Akebia Therapeutics Inc. (AKBA) and FibroGen Inc (FGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKBA and FGEN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- FGEN is the larger of the two at $1.34B, about 3.7x AKBA ($359.5M).
- AKBA has hit the wire 11 times in the past 4 weeks while FGEN has been quiet.
- FGEN has more recent analyst coverage (15 ratings vs 11 for AKBA).
- Company
- Akebia Therapeutics Inc.
- FibroGen Inc
- Price
- -
- -
- Market cap
- $359.5M
- $1.34B
- 1M return
- +36.46%
- -
- 1Y return
- -65.28%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2014
- News (4w)
- 11
- 0
- Recent ratings
- 11
- 15
Akebia Therapeutics Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Latest AKBA
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SVP, CFO, CBO & Treasurer Ostrowski Erik sold $62,181 worth of shares (56,019 units at $1.11), decreasing direct ownership by 8% to 616,616 units (SEC Form 4) to satisfy withholding tax
- Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
- Director Wolf Myles was granted 35,700 shares, increasing direct ownership by 27% to 169,081 units (SEC Form 4)
- Director Smith Cynthia was granted 35,700 shares, increasing direct ownership by 22% to 196,633 units (SEC Form 4)
- Director Rogers Michael W was granted 35,700 shares, increasing direct ownership by 22% to 197,429 units (SEC Form 4)
- Director Frieson Ron was granted 35,700 shares, increasing direct ownership by 28% to 165,200 units (SEC Form 4)
- Akebia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 33% to 145,100 units (SEC Form 4)
Latest FGEN
- Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
- Kyntra Bio to Participate in Upcoming Investor Conferences
- FibroGen Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
- Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
- Chief Financial Officer Delucia David covered exercise/tax liability with 52 shares, decreasing direct ownership by 1% to 4,489 units (SEC Form 4)
- CEO Wettig Thane covered exercise/tax liability with 259 shares, decreasing direct ownership by 1% to 24,680 units (SEC Form 4)
- FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
- CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)